暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股期权个股详情
RCUS240517C12500
- 4.30
- -0.91-17.47%
延时15分钟行情收盘价 05/17 15:59 (美东)
5.48最高价4.12最低价
5.48今开5.21昨收3428张成交量3552张未平仓合约数12.50行权价154.18万成交额5542.94%隐含波动率5.62%溢价2024/05/17到期日4.40内在价值100合约乘数-1天距到期日0.00时间价值100合约规模美式期权类型0.8158Delta0.0353Gamma3.16杠杆倍数-43.1150Theta0.0000Rho2.58有效杠杆0.0004Vega
分时
- 5日
- 日K
新闻
快讯 | 纽约证券交易所订单失衡 58165.0 股买入方
基于Domvanalimab的预期疗效和安全性，Arcus Biosciences的乐观买入评级
Arcus Biosciences的买入评级：独特的抗Tigit抗体和有前途的癌症试验激发了乐观情绪
快讯 | Arcus Biosciences Inc.：摩根士丹利将目标价格从38.00美元上调至40.00美元
默沙东停止实验性皮肤癌组合疗法的测试
分析师刚刚对Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS）的估计进行了令人眼花缭乱的升级
Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS）的股东今天将有理由微笑，分析师对今年的法定预测进行了大幅上调。分析师大大增加了
评论
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
The recent sale of Arcus Biosciences shares by the COO and the lack of insider buying over the last year raises caution. The level of insider ownership indicates some alignment between management and smaller shareholders, but it's not particularly high.
1
Despite a moderate P/S ratio, the company's revenue growth lags behind others, potentially problematic if the trend persists. Muted future growth estimates compared to the industry could lead to disappointment if the P/S aligns with the growth outlook.
Arcus Biosciences' cash runway is promising despite a significant drop in revenue. However, shareholders may face costly dilution if the company sells shares to cover another year's operations. The falling revenue is concerning for the cash burning company.
Despite the weaker earnings outlook, the consensus price target suggests analysts do not anticipate a long-term impact on the company’s valuation. However, the downgrade of next year's forecast instills caution regarding Arcus Biosciences' future performance.
阅读更多